A Trailblazer on the Genetic Frontier

Transgene's Margaret Liu talks about DNA-based vaccine's potential for revolutionizing the treatment of cancer and other complex diseases

Dr. Margaret A. Liu, vice-chairman of Transgene SA (TRGNY ) and visiting professor at Karolinska Institutet in Stockholm, is working on developing new technologies for new vaccines and cancer immunotherapy. These cancer treatments are similar to a vaccine in that they use the body's immune system to attack the cancer. Not preventative vaccines, they would be given as a therapy to treat cancer. She spoke with BusinessWeek Correspondent Amy Barrett about innovations in vaccines and the hurdles that need to be overcome.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.